The unanswered question: what is the determinant of S-1 pharmacokinetics?
Ichikawa
W
W
Fujita
K
K
Sasaki
Y
Y
D000483:Alleles; D000964:Antimetabolites, Antineoplastic / Q000493:pharmacokinetics*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics* / Q000378:metabolism; D044466:Asian People / Q000235:genetics*; D049628:Body Size; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D065637:Cytochrome P-450 CYP2A6; D004338:Drug Combinations; D005472:Fluorouracil / Q000493:pharmacokinetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D010094:Oxonic Acid / Q000493:pharmacokinetics*; D005641:Tegafur / Q000493:pharmacokinetics*
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D001189:Aryl Hydrocarbon Hydroxylases; D065637:Cytochrome P-450 CYP2A6; D005472:Fluorouracil